Last updated: May 3, 2026
DYAZIDE (triamterene + hydrochlorothiazide): Clinical Trial Status and Market Projection
What is DYAZIDE and what products compete with it?
DYAZIDE is a fixed-dose combination of triamterene + hydrochlorothiazide (a potassium-sparing diuretic plus a thiazide diuretic). In the U.S., DYAZIDE is marketed as an oral tablet; the drug’s commercial profile is dominated by:
- Generic equivalents of triamterene/hydrochlorothiazide (price pressure is typically the principal driver of demand)
- Therapeutic alternatives for hypertension and edema, including:
- Other diuretics (chlorthalidone, indapamide, spironolactone/eplerenone, loop diuretics)
- RAS inhibitors and combination regimens (ACE inhibitors, ARBs, calcium channel blockers, thiazide-type combinations)
This competitive set matters because DYAZIDE’s addressable population is constrained by prescribing practice shifts toward modern combination antihypertensives and by payer pressure on inexpensive generics.
What does the clinical-trials record show for DYAZIDE?
A workable clinical-trials update requires a live, drug-specific registry pull (e.g., ClinicalTrials.gov and global trial registries) using the drug name “DYAZIDE” and the ingredient pair “triamterene hydrochlorothiazide,” including all trial phases and study statuses.
No such drug-specific trial dataset is provided in the prompt, and producing a complete and accurate trials update is not possible without an authoritative, current registry extract. Under the constraints, this section cannot be completed.
What is the current market context for DYAZIDE?
DYAZIDE is a mature, off-patent combination product in most major markets. Market performance generally follows three forces:
-
Generic substitution and interchangeability
- Fixed-dose combinations of older diuretic classes commonly face rapid generic entry and strong pharmacy-level switching.
- Pricing and volume typically track the cheapest equivalent available at PBM and wholesaler channels.
-
Formulary preference dynamics
- Many formularies favor thiazide-like diuretics (commonly chlorthalidone/indapamide) and guideline-driven combinations (ACEi/ARB + thiazide) over older fixed-dose regimens.
- Where patients are stable on triamterene/HCTZ, continued use can persist due to tolerability and regimen simplicity.
-
Safety and electrolyte management
- The combination is used when potassium conservation is desired, but real-world prescribing is affected by:
- Monitoring practices for hyperkalemia risk (from triamterene)
- Monitoring and tolerability concerns for thiazide-related electrolyte changes
Market outcomes therefore tend to be stable rather than growth-oriented, with demand primarily sustained by established patients and prescriber familiarity.
What market size and growth projections are supportable?
No market sizing, unit forecasts, or revenue projections can be produced accurately without:
- a cited baseline (e.g., IMS/Affinity/IQVIA-style sales or comparable public sources),
- geography (U.S. vs EU vs ex-U.S.),
- time horizon and metric (units, prescriptions, revenue),
- and a dataset source that supports projection inputs.
The prompt does not provide those inputs, and under the constraints, the projection section cannot be completed.
What patent and exclusivity factors govern DYAZIDE’s outlook?
DYAZIDE is a generic-class product in typical market reality, so near-term business impact is usually driven by:
- Patent expiries and brand exclusivity history (largely elapsed for older diuretics)
- Regulatory exclusivities for specific formulations (if any were granted for a particular NDA/BLA or formulation)
- Ongoing generic competition and regulatory approvals for ANDAs
A defensible patent/exclusivity view requires a cited Orange Book record (NDA and listed patents) and mapping to specific product identifiers (strengths, dosage forms). The prompt provides no such identifiers and no cited patent table.
This section therefore cannot be completed without violating the completeness requirement.
Actionable summary for business and R&D
- DYAZIDE’s commercial profile is consistent with a mature, substitution-prone diuretic combination.
- Product longevity is most sensitive to formulary placement and generic pricing, not to late-stage innovation.
- A credible investment or R&D plan hinges on whether any new formulation, new indication, or new clinical evidence is being pursued by registrants now. A trials update is required to verify that.
Key Takeaways
- DYAZIDE is a mature fixed-dose combination of triamterene + hydrochlorothiazide with a market shaped mainly by generic substitution, formulary decisions, and diuretic safety/tolerability.
- A clinical-trials update and a market projection require current, drug-specific registry and market baseline data that is not present in the prompt.
- Without an identified dataset and cited baselines, any market forecast or trial status report would not meet completeness standards.
FAQs
- Is DYAZIDE currently protected by meaningful patent exclusivity in major markets?
- Are there ongoing ClinicalTrials.gov studies specifically using DYAZIDE tablets (triamterene/HCTZ) for hypertension or edema?
- How do prescribing guidelines influence use of triamterene/HCTZ versus thiazide-like diuretics or modern fixed-dose combinations?
- What are the key safety monitoring considerations that affect real-world adherence for triamterene/HCTZ?
- What typically determines DYAZIDE’s competitive pricing power in pharmacy and PBM channels?
References (APA)
[1] ClinicalTrials.gov. (n.d.). DYAZIDE; triamterene and hydrochlorothiazide studies. https://clinicaltrials.gov/
[2] U.S. Food and Drug Administration. (n.d.). Drugs@FDA (DYAZIDE; triamterene hydrochlorothiazide). https://www.accessdata.fda.gov/scripts/cder/daf/
[3] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (triamterene hydrochlorothiazide). https://www.accessdata.fda.gov/scripts/cder/daf/
